Vitamin D supplementation and risk of toxicity in pediatrics: A review of current literature

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1132-1141

  Vogiatzi, Maria G ^a   Jacobson Dickman, Elka ^b   DeBoer, Mark D ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE FACTORS; CHILD; DIETARY SUPPLEMENTS; HUMANS; HYPERCALCEMIA; HYPERCALCIURIA; NEPHROCALCINOSIS; RECOMMENDED DIETARY ALLOWANCES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84898457135     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3655     Document Type: Review

References (101)

1. Kimball S, Fuleihan Gel-H, Vieth R. Vitamin D: a growing perspective. Crit Rev Clin Lab Sci. 2008;45:339-414.
2. Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res. 2007;22:V28-V33.
3. Holick MF. The D-lightful vitamin D for child health. JPEN J Parenter Enteral Nutr. 2012;36(1 suppl):9S-19S.
4. Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial US adolescent population: the National Health and Nutrition Examination Survey III. Pediatrics. 2009;123(3):797-803.
5. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.
6. Ross AC, MansonJE, Abrams SA, etal. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J ClinEndocrinolMetab. 2011; 96:1911-1930.
8. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97:1153-1158.
9. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. JClin Endocri-nolMetab. 2012;97:1146-1152.
10. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122:398-417.
11. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122: 1142-1152.
12. EFSAPanelon DieteticProducts, NutritionandAllergies. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA J. 2012;10:2813.
13. Braegger C, Campoy C, Colomb V, et al. Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr. 2013;56:692-701.
14. Araki T, Holick MF, Alfonso BD, et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J Clin Endocrinol Metab. 2011;96:3603-3608.
15. Ashizawa N, Arakawa S, Koide Y, Toda G, Seto S, Yano K. Hy-percalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern Med. 2003;42: 340-344.
16. Granado-Lorencio F, Rubio E, Blanco-Navarro I, Perez-Sacristan B, Rodriguez-Pena R, Garcia Lopez FJ. Hypercalcemia, hypervi-taminosis A and 3-epi-25-OH-D3 levels after consumption of an "over the counter" vitamin D remedy. A case report. Food Chem Toxicol. 2012;50:2106-2108.
17. Kaptein S, Risselada AJ, Boerma EC, Egbers PH, Nieboer P. Life-threatening complications of vitamin D intoxication due to over-the-counter supplements. Clin Toxicol (Phila). 2010;48:460-462.
18. Klontz KC, Acheson DW. Dietary supplement-induced vitamin D intoxication. N Engl J Med. 2007;357:308-309.
19. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med. 2001; 345:66-67.
20. Naik MA, Banday KA, Najar MS, Reshi AR, Bhat MA. Vitamin D intoxication presenting as acute renal failure. Indian J Nephrol. 2008;18:125-126.
21. Nordt SP, Williams SR, Clark RF. Pharmacologic misadventure resulting in hypercalcemia from vitamin D intoxication. J Emerg Med. 2002;22:302-303.
22. Pandita KK, Pandita S, Hassan T. "Toxic" beef bone soup. Clin Cases Miner Bone Metab. 2011;8:43-44.
23. Taskapan H, Vieth R, Oreopoulos DG. Unusually prolonged vitamin D intoxication after discontinuation of vitamin D: possible role of primary hyperparathyroidism. Int Urol Nephrol. 2008;40: 801-805.
24. Atabek ME, Pirgon O, Sert A. Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. J Pe-diatr Endocrinol Metab. 2006;19:169-172.
25. Barrueto FJr,Wang-Flores HH, Howland MA, Hoffman RS, Nelson LS. Acute vitamin D intoxication in a child. Pediatrics. 2005; 116:e453-e456.
26. Bereket A, Erdogan T. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics. 2003;111:899-901.
27. Chambellan-Tison C, Horen B, Plat-Wilson G, Moulin P, Claudet I. Severe hypercalcemia due to vitamin D intoxication [in French]. Arch Pediatr. 2007;14:1328-1332.
28. Chatterjee M, Speiser PW. Pamidronate treatment of hypercalce-mia caused by vitamin D toxicity. J Pediatr Endocrinol Metab. 2007;20:1241-1248.
29. Doneray H, Ozkan B, Caner I, Ozkan A, Karakelleoglu C. Intra-gastric alendronate therapy in two infants with vitamin D intoxication: a new method. Clin Toxicol (Phila). 2008;46:300-302.
30. Ezgu FS, Buyan N, Gunduz M, Turner L, Okur I, Hasanoglu A. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions. Eur JPediatr. 2004;163:163-165.
31. Hatun S, Cizmecioglu F. Use of alendronate in the treatment of vitamin D intoxication in infants. Turk J Pediatr. 2005;47:373-375.
32. Orbak Z, Doneray H, Keskin F, Turgut A, Alp H, Karakelleoglu C. Vitamin D intoxication and therapy with alendronate (case report and review of literature). Eur J Pediatr. 2006;165:583-584.
33. Rajakumar K, Reis EC, Holick MF. Dosing error with over-the-counter vitamin D supplement: a risk for vitamin D toxicity in infants. Clin Pediatr (Phila). 2013;52:82-85.
34. Sezer RG, Guran T, Paket^i C, Seren LP, Bozaykut A, Bereket A.Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication. Acta Paediatrica. 2012; 101:e122-e125.
35. Joshi R. Hypercalcemia due to hypervitaminosis D: report of seven patients. J Trop Pediatr. 2009;55:396-398.
36. Vanstone MB, Oberfield SE, Shader L, Ardeshirpour L, Carpenter TO. Hypercalcemia in children receiving pharmacologic doses of vitamin D. Pediatrics. 2012;129:e1060-e1063.
37. de Paula FJ, Rosen CJ. Vitamin D safety and requirements. Arch Biochem Biophys. 2012;523:64-72.
38. Shroff R, Knott C, Rees L. The virtues of vitamin D-but how much is too much? Pediatr Nephrol. 2010;25:1607-1620.
39. Jones G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu Rev Nutr 2013;33:23-44.
40. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvi-tamin D status: a systematic review and meta-analysis. Am JClin Nutr. 2012;95:1357-1364.
41. Deluca HF, Prahl JM, Plum LA. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys. 2011;505:226-230.
42. Jones G. Pharmacokinetics of vitamin D toxicity. Am JClin Nutr. 2008;88:582S-586S.
43. PettiforJM, Bikle DD, Cavaleros M, Zachen D, Kamdar MC, Ross FP. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med. 1995;122:511-513.
44. Bouillon R, Van Cromphaut S, Carmeliet G. Intestinal calcium absorption: molecular vitamin D mediated mechanisms. J Cell Biochem. 2003;88:332-339.
45. Bell TD, Demay MB, Burnett-Bowie SA. The biology and pathology of vitamin D control in bone. J Cell Biochem. 2010;111:7-13.
46. Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol. 1993;264:F181-F198.
47. Hoenderop JG, Nilius B, Bindels RJ. Molecular mechanism of active Ca2 + reabsorption in the distal nephron. Annu Rev Physiol. 2002;64:529-549.
48. Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest. 1992;90:749-758.
49. Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int. 1996;50:2129-2139.
50. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2 + )-induced inhibition of apical K+ channels in the TAL. Am J Physiol. 1996;271:C103-C111.
51. Sands JM, Naruse M, Baum M, et al. Apical extracellular calcium/ polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest. 1997;99:1399-1405.
52. Salusky IB. Bone and mineral metabolism in childhood end-stage renal disease. Pediatr Clin North Am. 1995;42:1531-1550.
53. Koch M, Kohnle M. Successful off-label use of cinacalcet HCl after standard therapy failure in a young man with pseudohypopara-thyroidism Type 1b and vitamin D intoxication sequelae. Clin Nephrol. 2008;70:439-444.
54. Schroth M, Dotsch J, Dorr HG. Hypercalcemia and idiopathic hypoparathyroidism. JClin Pharm Ther. 2001;26:453-455.
55. Stickler GB, Morgenstern BZ. Hypophosphataemic rickets: final height and clinical symptoms in adults. Lancet. 1989;2:902-905.
56. Holmlund-Suila E, Viljakainen H, Hytinantti T, Lamberg-Allardt C, Andersson S, Makitie O. High-dose vitamin d intervention in infants-effects on vitamin d status, calcium homeostasis, and bone strength. J Clin Endocrinol Metab. 2012;97:4139-4147.
57. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: A randomized controlled trial. J Clin Endocrinol Metab. 2006;91: 405-412.
58. Maalouf J, Nabulsi M, Vieth R, et al. Short-and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab . 2008;93:2693-2701.
59. Gallo S, Comeau K, Vanstone C, et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial. JAMA. 2013;309:1785-1792.
60. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial [published correction appears in JAMA. 2010; 303:2357]. JAMA. 2010;303:1815-1822.
61. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology. 2007;46:1852-1857.
62. Sanders KM, Nicholson GC, Ebeling PR. Is high dose vitamin D harmful? Calcif Tissue Int. 2013;92:191-206.
63. Jeans PC, Stearns G. The effect of vitamin D on linear growth in infancy: II. The effect of intakes above 1,800 U.S.P. units daily. J Pediatr. 1938;13:730-740.
64. Markestad T, Hesse V, Siebenhuner M, et al. Intermittent high-dose vitamin D prophylaxis during infancy: effect on vitamin D metabolites, calcium, and phosphorus. Am J Clin Nutr. 1987;46: 652-658.
65. Cesur Y, Caksen H, Gundem A, Kirimi E, Odabas D. Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets. J Pediatr Endocrinol Metab. 2003;16:1105-1109.
66. Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr. 1994;125:487-490.
67. Zeghoud F, Ben-Mekhbi H, Djeghri N, Garabedian M. Vitamin D prophylaxis during infancy: comparison of the long-term effects of three intermittent doses (15, 5, or 2.5 mg) on 25-hydroxyvitamin D concentrations. Am J Clin Nutr. 1994;60:393-396.
68. Gordon CM, Williams AL, Feldman HA, et al. Treatment of hy-povitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93:2716-2721.
69. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358:1500-1503.
70. Abrams SA, Hawthorne KM, Chen Z. Supplementation with 1000 IU vitamin D/d leads to parathyroid hormone suppression, but not increased fractional calcium absorption, in 4-8-y-old children: a double-blind randomized controlled trial. Am J Clin Nutr. 2013; 97:217-223.
71. Dong Y, Stallmann-Jorgensen IS, Pollock NK, et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95: 4584-4591.
72. Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97:2134-2142.
73. Benchimol EI, Ward LM, Gallagher JC, et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:538-545.
74. Boas SR, Hageman JR, Ho LT, Liveris M. Very high-dose ergo-calciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009;8:270-272.
75. Green D, Carson K, Leonard A, et al. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008;153:554-559.
76. Green DM, Leonard AR, Paranjape SM, Rosenstein BJ, Zeitlin PL, Mogayzel PJ. Transient effectiveness of vitamin D2 therapy in pe-diatric cystic fibrosis patients. J Cyst Fibros. 2010;9:143-149.
77. Havens PL, Mulligan K, Hazra R, et al. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97: 4004-4013.
78. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvi-tamin D concentrations in HIV-infected children and adolescents [published correction appears in Pediatrics. 2009;123:1437]. Pediatrics. 2009;123:e121-e126.
79. Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis. 2012;54:1013-1025.
80. Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, Bitnun A. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011;159:951-957.
81. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013;92:118-127.
82. Singh RJ. Quantitation of 25-OH-vitaminD (25OHD) usingliquid tandem mass spectrometry (LC-MS-MS). Methods Mol Biol. 2010; 603:509-517.
83. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180-188.
84. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr. 2009;89:634-640.
85. Hunter D, De Lange M, Snieder H, et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res. 2001;16:371-378.
86. Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365:410-421.
87. Dauber A, Nguyen TT, Sochett E, et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. JClin Endocrinol Metab. 2012;97: E268-E274.
88. Nguyen M, Boutignon H, Mallet E, et al. Infantile hypercalcemia and hypercalciuria: newinsights into a vitamin D-dependent mechanism and response to ketoconazole treatment. J Pediatr. 2010; 157:296-302.
89. Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia, hyper-calciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ke-toconazole therapy. J Clin Endocrinol Metab. 2012;97:E423-E427.
90. Bouillon R. Genetic and environmental determinants of vitamin D status. The Lancet. 2010;376:148-149.
91. Blank S, Scanlon KS, Sinks TH, Lett S, Falk H. An outbreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy. Am J Public Health. 1995;85:656-659.
92. Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW. Hypervitaminosis D associated with drinking milk. NEngl J Med. 1992;326:1173-1177.
93. Koul PA, Ahmad SH, Ahmad F, Jan RA, Shah SU, Khan UH. Vitamin D toxicity in adults: a case series from an area with endemic hypovitaminosis D. Oman Med J. 2011;26:201-204.
94. Lowe H, Cusano NE, Binkley N, Blaner WS, Bilezikian JP. Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican Republic. J Clin Endocrinol Metab . 2011;96: 291-295.
95. LeBlanc ES, Perrin N, Johnson JD Jr, Ballatore A, Hillier T. Over-the-counter and compounded vitamin D: is potency what we expect? JAMA Intern Med. 2013;173:585-586.
96. Samuel HS. Vitamin D as a public health problem. Br Med J. 1964; 1:1654-1655.
97. Ammenti A, Pelizzoni A, Cecconi M, Molinari PP, Montini G. Nephrocalcinosis in children: a retrospective multi-centre study. Acta Paediatrica. 2009;98:1628-1631.
98. Sjoden G, Lindgren U. The effect of prednisolone on kidney calcification in vitamin D-treated rats. Calcif Tissue Int. 1985;37: 613-616.
99. Porcel SL, Cumplido JA, de la Hoz B, Cuevas M, Losada E. Ana-phylaxis to calcitonin. Allergol Immunopathol (Madr). 2000;28: 243-245.
100. Gurkan F, Davutoglu M, Bosnak M, Ece A, Dikici B, Bilici M, Haspolat K. Pamidronate treatment in acute vitamin D intoxication. J Endocrinol Invest. 2004;27:680-682.
101. Selby PL, Davies M, Marks JS, MawerEB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. ClinEndocrinol(Oxf). 1995;43:531-536.